rimary percutaneous coronary intervention (PCI) has been shown to be superior to thrombolysis for patients with acute myocardial infarction (AMI). 1 Although primary stenting has reduced restenosis as compared to balloon angioplasty in patients with AMI, the incidence of restenosis was still considerably high even after PCI. Drug-eluting stents (DES) have dramatically reduced the risk of restenosis and target vessel revascularization (TVR) after elective PCI as compared with bare metal stents (BMS). 2, 3 Several studies have investigated the safety and efficacy of primary stenting with DES for AMI, 4-7 but the long-term clinical outcome of DES for AMI remains controversial. The aim of the present study was to assess the long-term safety and efficacy of primary PCI with DES in Japanese patients with AMI.
Methods

Subjects
Between August 2004 and July 2006, a total of 205 consecutive patients with AMI underwent coronary angiography within 24 h after the onset of chest pain at Hiroshima City Hospital. AMI was diagnosed as chest pain consistent with ongoing myocardial ischemia persisting >30 min with concomitant electrocardiographic change. Serum creatine kinase was measured every 3 h, and peak creatine kinase had to be more than twice the normal upper limit to be accepted. Twenty-one patients with cardiogenic shock, 18 patients who had primary PCI with BMS, and 23 patients with no stenting, were excluded from the analysis. Primary PCI with sirolimuseluting stents (SES) was performed in the remaining 143 patients, who comprised the SES group ( Figure 1A) .
Between August 2002 and July 2004, 168 patients with AMI underwent coronary angiography within 24 h after chest pain at Hiroshima City Hospital. Nineteen patients with cardiogenic shock and 18 patients without stenting, were excluded from the present analysis. Two patients suffered from recurrent myocardial infarction (MI) in the 2-year period, and we excluded the second admission for recurrent MI from the pres-
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ent study. We performed primary PCI with BMS in the remaining 129 patients, who served as the historical control (BMS group; Figure 1A ). Informed consent was obtained from each patient. The study protocol was reviewed and approved by the ethics committee of Hiroshima City Hospital.
Angioplasty Procedure
Primary PCI was performed in a conventional manner as previously reported. Since August 2004 when DES became commercially available in Japan, primary PCI with DES has been encouraged as the choice of treatment for patients with AMI otherwise contraindicated. Use of thrombectomy or predilatation with a conventional balloon depended on the physician's decision.
The perfusion status of the infarct-related coronary artery was determined in accordance with the Thrombolysis In Myocardial Infarction (TIMI) study classification. The initial TIMI Three-year follow-up chart. AMI, acute myocardial infarction; BMS, bare metal stents; CABG, coronary artery bypass grafting; Pts, patients; SES, sirolimus-eluting stents. 3-Year Outcomes of Sirolimus-Eluting Stents flow grade was assessed before the initiation of reperfusion therapy, and the final TIMI flow grade was assessed from the final angiography image. Coronary stenosis was visually assessed. Multi-vessel coronary disease was defined as the presence of lesions causing 75% stenosis in ≥1 vessels remote from the infarct-related artery. Left main coronary disease of 50% was considered to be at least 2-vessel disease. Collateral circulation was defined as partial or complete filling of the infarct-related artery distal to the infarct lesion.
Medication
Before coronary angiography, aspirin (330 mg), ticlopidine (100 mg), and cilostazol (100 mg) were given. After the procedure, we prescribed aspirin (100 mg) and ticlopidine (200 mg) daily. Cilostazol (200 mg) was given for 3 days. The use of heparin after the procedure was left to the decision of the operator.
Follow-up
All adverse events were recorded during the hospital stay. Follow-up data were collected for up to 3 years at outpatient visits and via telephone with the home doctors.
Study Endpoints and Definitions
The main endpoint was the occurrence of major adverse cardiovascular events (MACE). MACE was defined as death associated with cardiovascular events, recurrent MI, early and late stent thrombosis (LST), coronary artery bypass grafting (CABG), stroke, and/or TVR. Death associated with cardiovascular events was defined as that excluding non-cardiac death. Recurrent MI was defined as the recurrence of clinical symptoms or the occurrence of electrocardiographic changes accompanied by a new elevation in levels of creatine kinase, creatine kinase MB enzyme, or both. TVR was considered to be driven by ischemia if the stenosis of the target vessel was ≥50% of the luminal diameter, with either electrocardiographic changes while the patient was at rest, or a functional investigation indicating ischemia in the distribution of the target vessel, or if there was stenosis of ≥75% in conjunction with recurrent symptoms alone. 8 Stent thrombosis was defined as definitive or probable thrombosis according to the Academic Research Consortium (ARC) definition. 9 Follow-up angiography was encouraged but was not requisite.
Statistical Analysis
Data are given as mean ± SD. We tested the significance of the difference using the chi-square test for categorical variables. Student's t-test was used for continuous variables. Cumulative 3-year events were analyzed using the Kaplan-Meier method and compared using log-rank test. Cox's proportional hazard regression was used to identify independent predictors of mortality, adjusting for baseline clinical angiographic characteristics that included age, sex, hypertension, diabetes mellitus, current smoking, previous MI, Killip class, ST segment elevated MI, infarct location, initial occlusion of the infarct artery, multi-vessel disease and final reperfusion, and were given as hazard ratio (HR) and 95% confidence interval (CI). We used JMP version 5.0.1J (SAS Institute, Cary, NC, USA) for all statistical tests. A significance level of 0.05 was used and 2-tailed tests were applied.
Results
Baseline Characteristics
Baseline clinical and angiographic patient characteristics at enrollment are listed in Table 1 . There was no significant difference between the SES group and BMS group, except for current smoking, which tended to be more prevalent in the SES group. Procedural results are given in Table 2 . There was no significant difference in dual anti-platelet therapy at hospital discharge (99.3% and 96.9%; P=0.26). Data given as n (%) or mean ± SD. PCI, percutaneous coronary intervention; IVUS, intravascular ultrasound. Other abbreviations see in Table 1 . 
Long-Term Clinical Follow-up
Patients were followed up for a median of 1,801 days (maximum, 3,136 days). The 3-year follow-up chart is given in Figure 1B . Complete datasets were available for 133 of 143 patients (93%) in the SES group and for 118 of 129 patients (91.5%) in the BMS group.
Outcomes
Composite clinical outcomes at 3-year follow-up are listed in Table 3 . The MACE rate at 3 years in the SES group was lower at 20.3% (27 patients in 3 years) than the 33.1% (41 patients) in the BMS group (P=0.01; Figure 2) . The difference was mainly driven by the difference in TVR: the TVR rate at 3 years was lower at 12.3% (16 patients in 3 years) than the 22.4% (27 patients) in the BMS group, (P=0.02; Figure 2 ). 
-Year Outcomes of Sirolimus-Eluting Stents
There was no significant difference in the rate of all-cause death, cardiovascular death, non-fatal MI, CABG, stroke and stent thrombosis between the 2 groups. Only 1 patient in the SES group suffered from very LST at 526 days after PCI. Dual anti-platelet therapy was prescribed for that patient for a time after hospital discharge, but was stopped by the patient. According to procedural characteristics (Table 2) , thrombectomy and post-PCI dilatation were more frequently performed in the SES group, whereas direct stent and intravascular ultrasound (IVUS) were more common in the BMS group. Stents were significantly longer and of smaller diameter in the SES group than the BMS group. Multivariate analysis showed that the SES group was independently associated with lower MACE (HR, 0.68; 95%CI: 0.50-0.92) and TVR (HR, 0.59; 95%CI: 0.40-0.86).
Discussion
This study has shown that primary PCI with SES in patients with AMI reduced the rate of MACE and TVR, compared with primary PCI with BMS at 3-year follow-up in nonselected Japanese patients. More importantly, there was no significant difference in the rate of death, non-fatal MI, CABG, stroke and stent thrombosis between the 2 groups. In addition, the use of BMS was associated with both increased MACE and TVR on multivariate analysis, using Cox's proportional hazard regression.
DES has been shown to be associated with significant reduction in restenosis and TVR. 2,3,10, 11 The incidence of LST and death, however, could be higher in DES than BMS. 12, 13 Several cohort studies have reported that off-label use of DES, especially for AMI, is associated with LST. 13-15 AMI, however, is also an important predictor of LST even after primary PCI with BMS. 16, 17 It remains unclear whether the use of DES for AMI increases the risk of LST as compared to BMS. Several randomized trials have compared primary PCI with DES to BMS. In the STRATEGY trial, Valgimigli et al compared SES plus tirofiban to BMS plus abciximab in 175 patients with ST-elevation MI. 18 At 2-year follow-up, SES was associated with a significant reduction of TVR, with a similar outcome in terms of death, recurrent MI, and stent thrombosis. Similar benefits have been observed in randomized trials such as the PASEO, SESAMI, and TYPHOON studies. [19] [20] [21] In addition to the studies carried out in Western countries, Park et al showed that mid-to long-term outcomes were better in patients receiving DES for AMI in Korea. 22 In a 3-year follow up of the randomized DEDICATION trial, however, the rate of cardiac death was higher in the DES group compared to the BMS group. 23 Most, but not all of these studies have demonstrated the safety and efficacy of DES in patients with AMI. In addition, it should be noted that patient selection bias might have influenced the favorable outcomes in these studies. The incidence of LST is generally higher in registry studies than in randomized trials.
It has been also suggested that there may be a difference in the incidence of LST between Caucasian and Japanese subjects. The data from the European large cohort study reported that LST occurred steadily at a constant rate of 0.6% per year up to 3 years after DES implantation. 15 In contrast, a Japanese cohort study from the j-CYPHER registry, showed that the cumulative incidence of LST was 0.2% per year up to 2 years after SES implantation. 24 They also reported that, among patients treated exclusively with SES, AMI was associated with greatest risk of stent thrombosis within the first year after PCI, but the risk of late adverse events after 1 year was similar between those with and without ACS and between those with AMI and those with unstable angina pectoris. Comparison with BMS, however, was lacking. In the current study, we showed that primary PCI with DES, as compared to BMS, reduced TVR without increased risk of LST in non-selected Japanese patients with AMI. 25 Hong et al showed that primary PCI was a predictor of late stent malapposition in BMS as well as in DES patients with AMI on IVUS. 26, 27 Shimohama et al, comparing SPIRIT III Japan to SPIRIT III USA, showed that post-procedure incomplete apposition was less frequently observed in SPIRIT III Japan. 28 In the j-CYPHER registry study, Kimura et al suggested that a high rate of IVUS guidance for stent procedures might have contributed to better stent deployment and complete apposition to the vessel wall. 24 In Japan, the use of PCI has expanded and has had an impact on therapy in patients with coronary artery disease after the introduction of DES. 29 PCI for coronary artery disease patients without any objective evidence of myocardial ischemia, however, has not improved life expectancy. 30 It has also been indicated that no randomized studies have demonstrated the usefulness of DES in the prevention of death and recurrent MI. 31 Further studies with longer follow-up periods are necessary to establish the safety and efficacy of DES in patients with AMI.
Study Limitations
The present study had limitations common to all retrospective investigations. All consecutive patients with AMI who underwent primary PCI with SES, however, were included in the study. Small sample size and single-center location were other limitations of the present study. Large registries may provide more useful information, but selection bias may vary among the participating institutions. At 3-year follow-up, the profile of anti-platelet therapy was unclear. Furthermore, the SES group might have received not only better medical therapy but also better PCI expertise than the BMS group, because they underwent implantation later. Indeed, all patients could not complete 3-year follow-up, but the follow-up rate was similar between the SES group and BMS group.
Conclusion
The present study suggests that SES for patients with AMI could be used effectively and safely, with reduced incidence of TVR, and with no difference in death, non-fatal MI, CABG, or stent thrombosis at 3-year follow-up in Japan, as compared to BMS.
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